Germany's G-BA publishes benefit assessment report on Lenvima

Germany’s Federal Joint Committee (G-BA) has published the benefit assessment report for Japanese pharma major Eisai’s (TYO: 4523) Lenvima (lenvatinib) for people with radioactive iodine refractory differentiated thyroid cancer (RAI refractory DTC).

The G-BA will now accept comments from concerned parties, including scientific and medical expert associations, via written statements on the benefit assessment report until 22 October 2015. Eisai says it will make a formal response to the benefit assessment report in due course.

"Eisai is confident that the G-BA will appreciate the significant therapeutic benefits lenvatinib offers to people in Germany. We will move quickly to provide our comments on a number of important areas in the benefit assessment report and look forward to the discussions in the forthcoming oral hearing with experts," commented Gary Hendler, president and chief executive of Eisai EMEA and president, Eisai Oncology global business unit.